ProCE Banner Activity

Phase III KEYNOTE-716 Update: Final DMFS Analysis of Adjuvant Pembrolizumab vs Placebo in Stage IIB/IIC Melanoma

Conference Coverage

In this updated analysis after a median follow-up of 39.4 months, adjuvant pembrolizumab continued to demonstrate a significant improvement in DMFS and RFS vs placebo in patients with resected stage IIB/IIC melanoma.

Released: June 12, 2023


Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


Supported by educational grants from Merck Sharp & Dohme Corp. and Regeneron Pharmaceuticals, Inc.

Merck Sharp & Dohme Corp.

Regeneron Pharmaceuticals, Inc